Author

V. A. Dartois

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:drug response / drug discovery· 5 Organism:human· 3 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Organism:bacteria (other)· 1 Assay:bulk RNA-seq· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

M. Zimmerman· 4 shared M. D. Zimmerman· 3 shared M. Gengenbacher· 3 shared T. Dick· 3 shared D. A. Negatu· 2 shared D. Schnappinger· 2 shared N. Ruecker· 2 shared A. E. Jerse· 1 shared

Activity by Year

2021-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

M. Zimmerman

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Mycobacterium tuberculosis DprE1 inhibitor OPC-167832 is active against Mycobacterium abscessus in vitro

J. P. Sarathy, M. Zimmerman, M. Gengenbacher, V. A. Dartois, T. Dick

OPC-167832, a DprE1 inhibitor active against Mycobacterium tuberculosis, shows in vitro activity against Mycobacterium abscessus but lacks efficacy in a mouse model due to moderate potency.

bioRxiv · Sep 14, 2022Microbiology

Strongly bactericidal all-oral β-lactam combinations for the treatment of Mycobacterium abscessus lung disease

D. A. Negatu, M. Zimmerman, V. A. Dartois, T. Dick

The paper evaluates oral β-lactam combinations with avibactam against Mycobacterium abscessus and identifies synergistic bactericidal effects.

bioRxiv · Jun 7, 2022Microbiology

Activity of Tricyclic Pyrrolopyrimidine Gyrase B Inhibitor against Mycobacterium abscessus

A. Madani, D. A. Negatu, A. E. Marrouni, R. Miller, C. Boyce, N. Murgolo, C. J. Bungard, M. Zimmerman, V. A. Dartois, M. Gengenbacher, D. B. Olsen, T. Dick

This study evaluates the activity of TPP8, a tricyclic pyrrolopyrimidine gyrase B inhibitor, against Mycobacterium abscessus in vitro, ex vivo, and in vivo.

bioRxiv · May 16, 2022Microbiology

A novel oral GyrB/ParE dual binding inhibitor effective against multidrug resistant Neisseria gonorrhoeae and other high-threat pathogens

S. Park, R. Russo, L. Westfall, R. Shrestha, M. Zimmerman, V. A. Dartois, N. Kurepina, B. Kreiswith, E. Singleton, S.-G. LI, N. Mittal, Y.-M. Ahn, j. Bilotta, K. L. Connolly, A. E. Jerse, , D. S. Perlin

The paper describes a novel oral inhibitor, JSF-2659, effective against multidrug-resistant Neisseria gonorrhoeae and other high-threat pathogens, with low potential for resistance development.

bioRxiv · Mar 23, 2022Microbiology

Novel regimens of bedaquiline-pyrazinamide combined with moxifloxacin, rifabutin, delamanid and/or OPC-167832 in murine tuberculosis models

E. Nuermberger, R. Tasneen, A. Garcia, P. J. Converse, M. D. Zimmerman, V. A. Dartois, E. V. Kurbatova, A. Vernon, W. Carr, J. E. Stout, K. E. Dooley

This paper tests novel tuberculosis treatment regimens in mice, finding that BZM-based regimens show improved sterilizing activity compared to standard care.

bioRxiv · Dec 21, 2021Microbiology

A chemical-genetic map of the pathways controlling drug potency in Mycobacterium tuberculosis

S. Li, N. C. Poulton, J. S. Chang, Z. A. Azadian, M. A. Dejusus, N. Ruecker, M. D. Zimmerman, K. Eckartt, B. Bosch, C. A. Engelhart, D. Sullivan, M. Gengenbacher, V. A. Dartois, D. Schnappinger, J. M. Rock

This study uses a CRISPR interference platform to map drug resistance pathways in Mtb, identifying new intrinsic and acquired resistance mechanisms and potential drug targets.

bioRxiv · Nov 27, 2021 · PreprintMicrobiology

Chemical-genetic interaction mapping links carbon metabolism and cell wall structure to tuberculosis drug efficacy

E.-I. Koh, P. O. Oluoch, N. Ruecker, M. K. Proulx, V. Soni, K. C. Murphy, K. G. Papavinasasundaram, C. J. Reames, C. Trujillo, A. Zaveri, M. D. Zimmerman, R. Aslebagh, R. E. Baker, S. A. Shaffer, K. M. Guinn, , C. M. Sassetti

This study maps chemical-genetic interactions in Mycobacterium tuberculosis to identify how carbon metabolism and cell wall structure affect drug efficacy, revealing environment-dependent and -independent interactions.

bioRxiv · Apr 8, 2021Microbiology